Kava vs Kratom: reported profiles and risk context

Kava is a plant from the Pacific Islands whose active compounds (kavalactones) interact with the CNS through GABA and other pathways, producing relaxation and social ease. Kratom is a Southeast Asian plant whose active compounds (mitragynine, 7-hydroxymitragynine) interact with opioid receptors. This opioid receptor activity is a fundamental pharmacological difference that shapes kratom's risk profile.

Kava is associated with relaxation, social ease, oral numbness and mild sedation. Kratom is associated with stimulant-like effects at lower amounts and sedating, opioid-like effects at higher amounts. Individual responses to both vary considerably. Effects depend on product, preparation, individual sensitivity and other factors.

• Kava's effects are described as relaxing and socially easing.
• Kratom's effects shift from stimulant-like to sedating depending on amount consumed.
• Kratom's opioid receptor activity distinguishes it from kava pharmacologically.
• Nausea is a commonly reported adverse effect with both substances.

Kava carries documented liver safety concerns — regulatory advisories exist in several countries. It is also sedating and carries meaningful interaction risk with alcohol and other sedatives. Kratom carries dependence and withdrawal risk due to its opioid receptor activity. The evidence base for kratom safety is limited compared to kava. Both substances interact with other CNS depressants.

Both kava and kratom interact with alcohol and other CNS depressants, compounding sedation. Kava may affect liver enzyme activity and medication metabolism. Kratom's opioid receptor activity means combination with opioids carries risk of additive respiratory depression — a serious documented concern. Neither should be combined with alcohol without understanding the interaction context.